Tryptophan

Tryptophan

SCHEMBL531307

NC(=O)C[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.84
KDM4E B2RXH2 3/20 0.84
MAPT P10636 3/20 0.84
LMNA P02545 2/20 0.84
TSHR P16473 2/20 0.84
BLM P54132 2/20 0.84
PMP22 Q01453 2/20 0.84
MEN1 O00255 2/20 0.84
MPO P05164 1/20 0.84
HIF1A Q16665 1/20 0.84
SMN1; SMN2 Q16637 1/20 0.60
APAF1 O14727 1/20 0.59
POLB P06746 1/20 0.59
RECQL P46063 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
HTR2A P28223 3/20 0.59
HTR1A P08908 2/20 0.59
HTR2C P28335 2/20 0.59
SLC6A4 P31645 2/20 0.59
HTR7 P34969 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Tryptophan SCHEMBL9407071 1.00 KMT2A (0.84) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL3443032 1.00 KMT2A (0.84) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL9488111 1.00 KMT2A (0.84) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL5016074 1.00 KMT2A (0.84) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL4296800 0.96 KMT2A (0.78) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL28697957 0.95 KDM4E (0.76) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL1640623 0.92 KMT2A (0.94) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL1640625 0.92 KMT2A (0.94) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL8020249 0.92 KMT2A (0.94) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL7645018 0.92 KMT2A (0.94) KMT2AKDM4EMAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642910-B1 Rationally designed antibodies ALEXION PHARMA INC (US) 2012-02-08 EP claimed
EP-1589034-B1 Rationally designed antibodies ALEXION PHARMA INC (US) 2008-11-19 EP claimed
EP-1642910-A1 Rationally designed antibodies ALEXION PHARMACEUTICALS, INC. (US) 2006-04-05 EP claimed
EP-1370589-B1 RATIONALLY DESIGNED ANTIBODIES ALEXION PHARMA INC (US) 2006-03-15 EP claimed
EP-1589034-A2 Rationally designed antibodies ALEXION PHARMACEUTICALS, INC. (US) 2005-10-26 EP claimed
US-20030049683-A1 Immunoglobulin for use in human therapeutics and diagnostics ALEXION PHARMACEUTICAL, INC. 2003-03-13 US claimed
WO-2014002571-A1 ANGIOTENSIN-CONVERTING-ENZYME INHIBITING DIPEPTIDE ヤマキ株式会社 (JP) 2014-01-03 WO disclosed
US-5312901-A Genetic engineering with immunoglobulins and proteins PHARMACIA LKB BIOTECHNOLOGY AB (SE) 1994-05-17 US disclosed
US-5141870-A Transforming plants with mutant fragment confers herbicide resistance E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-08-25 US disclosed
US-5082773-A Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G PHARMACIA LKB BIOTECHNOLOGY AB (SE) 1992-01-21 US disclosed
US-4956296-A GENETIC ENGINEERING GENEX CORPORATION (US) 1990-09-11 US disclosed
US-4954618-A IMMUNOGLOBULIN BINDER GENEX CORPORATION (US) 1990-09-04 US disclosed